ロード中...
Leber’s hereditary optic neuropathy: course of disease in consideration of idebenone treatment and type of mutation
PURPOSE: In September 2015, the first and so far only medication for treatment of Leber’s hereditary optic neuropathy (LHON) was approved in the EU. The drug in question is idebenone (©Raxone) and has been given to all newly diagnosed patients of the University Eye Hospital Tuebingen since the appro...
保存先:
| 出版年: | Graefes Arch Clin Exp Ophthalmol |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer Berlin Heidelberg
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8016777/ https://ncbi.nlm.nih.gov/pubmed/33337510 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00417-020-05045-4 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|